Adiponectin receptor expression in human malignant tissues

Sharon H. Chou, Sofia Tseleni-Balafouta, Hyun-Seuk Moon, John P. Chamberland, Xiaowen Liu, Nikolaos Kavantzas, Christos S. Mantzoros

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Adiponectin has been proposed to be a mediator of obesity-associated malignancies and to have direct antineoplastic effects acting via adiponectin receptors AdipoR1 and AdipoR2. We describe herein the expression of AdipoR1 and AdipoR2 in several cancers not previously studied. We used immunohistochemistry to assess expression of adiponectin receptors in archival specimens of renal cell carcinoma (n = 64), hepatocellular carcinoma (n = 123), melanoma (n = 20), cholangiocarcinoma (n = 20), transitional cell carcinoma of the bladder (n = 24), ovarian epithelial carcinoma (n = 63), cervical squamous cell carcinoma (n = 49), and adrenocortical carcinoma (n = 48). To compare expression in malignant versus nonmalignant tissues, we also studied AdipoR1 and AdipoR2 expression in pairs of renal cell carcinoma and adjacent healthy kidney tissue specimens by immunohistochemistry. We also studied mRNA expression in 45 specimens of renal cell carcinoma by real-time polymerase chain reaction. Finally, we utilized Western blotting to confirm the presence of adiponectin receptors and subsequently studied cell signaling pathways of adiponectin in the renal cancer cell line 786-O. Cancers associated with obesity were significantly more likely to express AdipoR1 than cancers not associated with obesity. Of the specimens of renal cell carcinoma, which is strongly associated with obesity, 93. 8% expressed AdipoR1 compared to 44. 9% of the specimens of cervical cell carcinoma, which is not associated with obesity (p < 0. 001). There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens. Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors. Finally, Western blotting confirmed the presence of AdipoR1 in the renal cancer cell line 786-O, and adiponectin activates in vitro several signaling pathways in this cell line. In summary, we report for the first time expression of AdipoR1 and AdipoR2 in the above cancers and that AdipoR1 is more ubiquitously expressed in obesity-associated cancers.

Original languageEnglish
Pages (from-to)136-145
Number of pages10
JournalHormones and Cancer
Volume1
Issue number3
DOIs
Publication statusPublished - 2010 Jun 10
Externally publishedYes

Fingerprint

Adiponectin Receptors
Obesity
Renal Cell Carcinoma
Adiponectin
Neoplasms
Kidney Neoplasms
Cell Line
Messenger RNA
Western Blotting
Immunohistochemistry
Adrenocortical Carcinoma
Carcinoma
Kidney
Cholangiocarcinoma
Transitional Cell Carcinoma
Antineoplastic Agents
Real-Time Polymerase Chain Reaction
Hepatocellular Carcinoma
Squamous Cell Carcinoma
Melanoma

Keywords

  • Adiponectin
  • Adiponectin receptor
  • Malignancy
  • Obesity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Cite this

Chou, S. H., Tseleni-Balafouta, S., Moon, H-S., Chamberland, J. P., Liu, X., Kavantzas, N., & Mantzoros, C. S. (2010). Adiponectin receptor expression in human malignant tissues. Hormones and Cancer, 1(3), 136-145. https://doi.org/10.1007/s12672-010-0017-7

Adiponectin receptor expression in human malignant tissues. / Chou, Sharon H.; Tseleni-Balafouta, Sofia; Moon, Hyun-Seuk; Chamberland, John P.; Liu, Xiaowen; Kavantzas, Nikolaos; Mantzoros, Christos S.

In: Hormones and Cancer, Vol. 1, No. 3, 10.06.2010, p. 136-145.

Research output: Contribution to journalArticle

Chou, SH, Tseleni-Balafouta, S, Moon, H-S, Chamberland, JP, Liu, X, Kavantzas, N & Mantzoros, CS 2010, 'Adiponectin receptor expression in human malignant tissues', Hormones and Cancer, vol. 1, no. 3, pp. 136-145. https://doi.org/10.1007/s12672-010-0017-7
Chou SH, Tseleni-Balafouta S, Moon H-S, Chamberland JP, Liu X, Kavantzas N et al. Adiponectin receptor expression in human malignant tissues. Hormones and Cancer. 2010 Jun 10;1(3):136-145. https://doi.org/10.1007/s12672-010-0017-7
Chou, Sharon H. ; Tseleni-Balafouta, Sofia ; Moon, Hyun-Seuk ; Chamberland, John P. ; Liu, Xiaowen ; Kavantzas, Nikolaos ; Mantzoros, Christos S. / Adiponectin receptor expression in human malignant tissues. In: Hormones and Cancer. 2010 ; Vol. 1, No. 3. pp. 136-145.
@article{3cd4d6907e1e4531a408086a7ff6c816,
title = "Adiponectin receptor expression in human malignant tissues",
abstract = "Adiponectin has been proposed to be a mediator of obesity-associated malignancies and to have direct antineoplastic effects acting via adiponectin receptors AdipoR1 and AdipoR2. We describe herein the expression of AdipoR1 and AdipoR2 in several cancers not previously studied. We used immunohistochemistry to assess expression of adiponectin receptors in archival specimens of renal cell carcinoma (n = 64), hepatocellular carcinoma (n = 123), melanoma (n = 20), cholangiocarcinoma (n = 20), transitional cell carcinoma of the bladder (n = 24), ovarian epithelial carcinoma (n = 63), cervical squamous cell carcinoma (n = 49), and adrenocortical carcinoma (n = 48). To compare expression in malignant versus nonmalignant tissues, we also studied AdipoR1 and AdipoR2 expression in pairs of renal cell carcinoma and adjacent healthy kidney tissue specimens by immunohistochemistry. We also studied mRNA expression in 45 specimens of renal cell carcinoma by real-time polymerase chain reaction. Finally, we utilized Western blotting to confirm the presence of adiponectin receptors and subsequently studied cell signaling pathways of adiponectin in the renal cancer cell line 786-O. Cancers associated with obesity were significantly more likely to express AdipoR1 than cancers not associated with obesity. Of the specimens of renal cell carcinoma, which is strongly associated with obesity, 93. 8{\%} expressed AdipoR1 compared to 44. 9{\%} of the specimens of cervical cell carcinoma, which is not associated with obesity (p < 0. 001). There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens. Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors. Finally, Western blotting confirmed the presence of AdipoR1 in the renal cancer cell line 786-O, and adiponectin activates in vitro several signaling pathways in this cell line. In summary, we report for the first time expression of AdipoR1 and AdipoR2 in the above cancers and that AdipoR1 is more ubiquitously expressed in obesity-associated cancers.",
keywords = "Adiponectin, Adiponectin receptor, Malignancy, Obesity",
author = "Chou, {Sharon H.} and Sofia Tseleni-Balafouta and Hyun-Seuk Moon and Chamberland, {John P.} and Xiaowen Liu and Nikolaos Kavantzas and Mantzoros, {Christos S.}",
year = "2010",
month = "6",
day = "10",
doi = "10.1007/s12672-010-0017-7",
language = "English",
volume = "1",
pages = "136--145",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "3",

}

TY - JOUR

T1 - Adiponectin receptor expression in human malignant tissues

AU - Chou, Sharon H.

AU - Tseleni-Balafouta, Sofia

AU - Moon, Hyun-Seuk

AU - Chamberland, John P.

AU - Liu, Xiaowen

AU - Kavantzas, Nikolaos

AU - Mantzoros, Christos S.

PY - 2010/6/10

Y1 - 2010/6/10

N2 - Adiponectin has been proposed to be a mediator of obesity-associated malignancies and to have direct antineoplastic effects acting via adiponectin receptors AdipoR1 and AdipoR2. We describe herein the expression of AdipoR1 and AdipoR2 in several cancers not previously studied. We used immunohistochemistry to assess expression of adiponectin receptors in archival specimens of renal cell carcinoma (n = 64), hepatocellular carcinoma (n = 123), melanoma (n = 20), cholangiocarcinoma (n = 20), transitional cell carcinoma of the bladder (n = 24), ovarian epithelial carcinoma (n = 63), cervical squamous cell carcinoma (n = 49), and adrenocortical carcinoma (n = 48). To compare expression in malignant versus nonmalignant tissues, we also studied AdipoR1 and AdipoR2 expression in pairs of renal cell carcinoma and adjacent healthy kidney tissue specimens by immunohistochemistry. We also studied mRNA expression in 45 specimens of renal cell carcinoma by real-time polymerase chain reaction. Finally, we utilized Western blotting to confirm the presence of adiponectin receptors and subsequently studied cell signaling pathways of adiponectin in the renal cancer cell line 786-O. Cancers associated with obesity were significantly more likely to express AdipoR1 than cancers not associated with obesity. Of the specimens of renal cell carcinoma, which is strongly associated with obesity, 93. 8% expressed AdipoR1 compared to 44. 9% of the specimens of cervical cell carcinoma, which is not associated with obesity (p < 0. 001). There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens. Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors. Finally, Western blotting confirmed the presence of AdipoR1 in the renal cancer cell line 786-O, and adiponectin activates in vitro several signaling pathways in this cell line. In summary, we report for the first time expression of AdipoR1 and AdipoR2 in the above cancers and that AdipoR1 is more ubiquitously expressed in obesity-associated cancers.

AB - Adiponectin has been proposed to be a mediator of obesity-associated malignancies and to have direct antineoplastic effects acting via adiponectin receptors AdipoR1 and AdipoR2. We describe herein the expression of AdipoR1 and AdipoR2 in several cancers not previously studied. We used immunohistochemistry to assess expression of adiponectin receptors in archival specimens of renal cell carcinoma (n = 64), hepatocellular carcinoma (n = 123), melanoma (n = 20), cholangiocarcinoma (n = 20), transitional cell carcinoma of the bladder (n = 24), ovarian epithelial carcinoma (n = 63), cervical squamous cell carcinoma (n = 49), and adrenocortical carcinoma (n = 48). To compare expression in malignant versus nonmalignant tissues, we also studied AdipoR1 and AdipoR2 expression in pairs of renal cell carcinoma and adjacent healthy kidney tissue specimens by immunohistochemistry. We also studied mRNA expression in 45 specimens of renal cell carcinoma by real-time polymerase chain reaction. Finally, we utilized Western blotting to confirm the presence of adiponectin receptors and subsequently studied cell signaling pathways of adiponectin in the renal cancer cell line 786-O. Cancers associated with obesity were significantly more likely to express AdipoR1 than cancers not associated with obesity. Of the specimens of renal cell carcinoma, which is strongly associated with obesity, 93. 8% expressed AdipoR1 compared to 44. 9% of the specimens of cervical cell carcinoma, which is not associated with obesity (p < 0. 001). There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens. Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors. Finally, Western blotting confirmed the presence of AdipoR1 in the renal cancer cell line 786-O, and adiponectin activates in vitro several signaling pathways in this cell line. In summary, we report for the first time expression of AdipoR1 and AdipoR2 in the above cancers and that AdipoR1 is more ubiquitously expressed in obesity-associated cancers.

KW - Adiponectin

KW - Adiponectin receptor

KW - Malignancy

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=77955553051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955553051&partnerID=8YFLogxK

U2 - 10.1007/s12672-010-0017-7

DO - 10.1007/s12672-010-0017-7

M3 - Article

C2 - 21761356

AN - SCOPUS:77955553051

VL - 1

SP - 136

EP - 145

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 3

ER -